Literature DB >> 26093888

Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats.

Brendan Collins1.   

Abstract

'Big data' is the collective name for the increasing capacity of information systems to collect and store large volumes of data, which are often unstructured and time stamped, and to analyse these data by using regression and other statistical techniques. This is a review of the potential applications of big data and health economics, using a SWOT (strengths, weaknesses, opportunities, threats) approach. In health economics, large pseudonymized databases, such as the planned care.data programme in the UK, have the potential to increase understanding of how drugs work in the real world, taking into account adherence, co-morbidities, interactions and side effects. This 'real-world evidence' has applications in individualized medicine. More routine and larger-scale cost and outcomes data collection will make health economic analyses more disease specific and population specific but may require new skill sets. There is potential for biomonitoring and lifestyle data to inform health economic analyses and public health policy.

Mesh:

Year:  2016        PMID: 26093888     DOI: 10.1007/s40273-015-0306-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  15 in total

1.  Trust me, I'm a surgeon

Authors: 
Journal:  BMJ       Date:  2000-04-01

2.  The road ahead for the Affordable Care Act.

Authors:  John E McDonough
Journal:  N Engl J Med       Date:  2012-07-02       Impact factor: 91.245

3.  Welfarism vs. extra-welfarism.

Authors:  Werner B F Brouwer; Anthony J Culyer; N Job A van Exel; Frans F H Rutten
Journal:  J Health Econ       Date:  2007-11-29       Impact factor: 3.883

4.  Patient confidentiality in a time of care.data.

Authors:  Julian Sheather; Sophie Brannan
Journal:  BMJ       Date:  2013-11-27

5.  Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis.

Authors:  P J Jenkins; N D Clement; D F Hamilton; P Gaston; J T Patton; C R Howie
Journal:  Bone Joint J       Date:  2013-01       Impact factor: 5.082

6.  23andMe and the FDA.

Authors:  George J Annas; Sherman Elias
Journal:  N Engl J Med       Date:  2014-02-12       Impact factor: 91.245

7.  Growth in health care data causing an evolution in the pharmaceutical industry.

Authors:  J Alan Menius; Matthew D Rousculp
Journal:  N C Med J       Date:  2014 May-Jun

8.  The Oregon experiment--effects of Medicaid on clinical outcomes.

Authors:  Katherine Baicker; Sarah L Taubman; Heidi L Allen; Mira Bernstein; Jonathan H Gruber; Joseph P Newhouse; Eric C Schneider; Bill J Wright; Alan M Zaslavsky; Amy N Finkelstein
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

9.  De-identification methods for open health data: the case of the Heritage Health Prize claims dataset.

Authors:  Khaled El Emam; Luk Arbuckle; Gunes Koru; Benjamin Eze; Lisa Gaudette; Emilio Neri; Sean Rose; Jeremy Howard; Jonathan Gluck
Journal:  J Med Internet Res       Date:  2012-02-27       Impact factor: 5.428

Review 10.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

View more
  18 in total

Review 1.  Big Data Science: Opportunities and Challenges to Address Minority Health and Health Disparities in the 21st Century.

Authors:  Xinzhi Zhang; Eliseo J Pérez-Stable; Philip E Bourne; Emmanuel Peprah; O Kenrik Duru; Nancy Breen; David Berrigan; Fred Wood; James S Jackson; David W S Wong; Joshua Denny
Journal:  Ethn Dis       Date:  2017-04-20       Impact factor: 1.847

2.  Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015.

Authors:  Paula K Lorgelly; Brett Doble; Rachel J Knott
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

3.  Impact of initial medication non-adherence on use of healthcare services and sick leave: a longitudinal study in a large primary care cohort in Spain.

Authors:  Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Ramón Sabés-Figuera; Marta Fajó-Pascual; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Patricia Moreno-Peral; Albert Sánchez-Niubó; Marian March-Pujol; Maria Rubio-Valera
Journal:  Br J Gen Pract       Date:  2017-07-31       Impact factor: 5.386

4.  Big Data analysis to improve care for people living with serious illness: The potential to use new emerging technology in palliative care.

Authors:  Amara Callistus Nwosu; Brendan Collins; Stephen Mason
Journal:  Palliat Med       Date:  2017-08-14       Impact factor: 4.762

5.  Economics of Palliative and End-of-Life Care in India: A Concept Paper.

Authors:  Arunangshu Ghoshal; Anuja Damani; Naveen Salins; Jayita Deodhar; M A Muckaden
Journal:  Indian J Palliat Care       Date:  2017 Oct-Dec

6.  A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.

Authors:  Jonathan Brett; Adam G Elshaug; R Sacha Bhatia; Kelsey Chalmers; Tim Badgery-Parker; Sallie-Anne Pearson
Journal:  Implement Sci       Date:  2017-05-03       Impact factor: 7.327

7.  Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis.

Authors:  Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

8.  Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.

Authors:  Yixi Chen; Gregory F Guzauskas; Chengming Gu; Bruce C M Wang; Wesley E Furnback; Guotong Xie; Peng Dong; Louis P Garrison
Journal:  J Pers Med       Date:  2016-11-02

Review 9.  Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.

Authors:  Maarten J IJzerman; Hendrik Koffijberg; Elisabeth Fenwick; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

10.  Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea.

Authors:  Seung Yong Choi; Hyun-A Lim; Hyeon Woo Yim; Young-Hoon Park
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.